Takeda

1493 articles about Takeda

• 

  Roche Claims Another Legal Victory Over Takeda in Hemophilia Patent Case

  9/22/2023

  A U.S. federal court upheld a prior ruling in favor of Roche’s Genentech, finding that its blockbuster hemophilia treatment Hemlibra did not infringe on patent protections held by Takeda’s Baxalta.

• Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

  9/13/2023

  Takeda announced five new partnerships to its Global Corporate Social Responsibility Program, which contribute to strengthening health systems in low- and middle-income countries.

• Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

  9/13/2023

  Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO ® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease.

• Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge

  9/12/2023

  Takeda Canada Inc. is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge, a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences.

• Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

  9/11/2023

  Takeda announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 inhibitor with next generation selectivity, in people with active psoriatic arthritis.

• 

  AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

  9/8/2023

  As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.
• 

  FDA Approves Generics of Takeda’s ADHD, Binge Eating Drug Vyvanse

  8/31/2023

  Amid a supply shortage of the attention-deficit/hyperactivity disorder and binge-eating disorder medication, the regulator has cleared a slew of generic drugs of Takeda’s Vyvanse pill.

• ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan

  8/28/2023

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.

• BridGene Biosciences Achieves the Second Preclinical Milestone in Takeda Collaboration

  8/28/2023

  BridGene Biosciences, Inc. announced a significant preclinical milestone in its collaboration with Takeda.

• 

  The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023

  8/23/2023

  Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.
• 

  Takeda, Denali Scrap Phase I Alzheimer’s Drug Showing ‘Narrow Therapeutic Window’

  8/9/2023

  The companies partnered to develop the antibody transport vehicle in late 2021, but will continue their 2018 agreement to pursue other drugs in preclinical development.
• 

  Takeda Likely to Drop Rare Genetic Disease Candidate After Phase II Fail

  7/28/2023

  Despite beating analyst expectations, Takeda sustains a mid-stage defeat in a rare genetic disorder, leaving the fate of an investigational enzyme replacement therapy uncertain.

• Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

  7/27/2023

  Takeda announced strong financial results for the first quarter of fiscal year 2023. Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing to a core operating profit margin of 30.8%.

• The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

  7/26/2023

  Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journal of Medicine.

• 

  Takeda Withdraws Dengue Vaccine Application After FDA Request for More Data

  7/12/2023

  Following the regulator’s request for more data beyond the scope of its Phase III TIDES trial, Takeda decided to voluntarily withdraw the Biologics License Application for its TAK-003 dengue vaccine.
• 

  Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement

  7/6/2023

  The companies have signed two other pacts over the last year. In the latest deal, Takeda gains access to F-star’s platform to produce tetravalent antibodies for undisclosed oncology targets.

• F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies

  7/5/2023

  F-star Therapeutics , an invoX company (“F-star”) , today announced that it has entered into a strategic discovery collaboration and licence agreement with Takeda.

• Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

  6/25/2023

  Takeda presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura, and pharmacokinetics characteristics of TAK-755, as well as long-term data on TAK-755 prophylaxis from a Phase 3b continuation study.

• 

  The Top Biotech Companies in California Hiring Now

  6/21/2023

  Here are the top biotech companies in California hiring now on BioSpace’s life sciences–focused job board.

• Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

  6/20/2023

  Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA ® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting.